Andrew J. Cowan, MD

Articles by Andrew J. Cowan, MD

Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 22nd 2022

Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells

ByAndrew J. Cowan, MD

February 17th 2020

The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.

Andrew J. Cowan, MD

Articles by Andrew J. Cowan, MD

Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells

Trending on CancerNetwork

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma